[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556874":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":32,"locations":38,"responsibleParty":57,"collaborators":21,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":21,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":21,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":21,"overallStatus":78,"whyStopped":21,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Shanghai Zhongshan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment group","EXPERIMENTAL","Cryoablation combined with PD-1 antibody and bevacizumab",[13,14],"Procedure: Cryoablation","Drug: PD-1 antibody and bevacizumab",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","Cryoablation","After the completion of screening, the subjects received cryoablation treatment",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","PD-1 antibody and bevacizumab","Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg\u002Fkg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg\u002Fkg, with 100 mL of normal saline) once every 3 weeks until disease progression.",[9],[28],{"name":29,"affiliation":30,"role":31},"Jian Zhou","Fudan University","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":21,"email":37},"Lingxiao Liu","CONTACT","+86-18616881019","liulingxiao2022@163.com",[39],{"facility":40,"status":21,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Zhongshan Hospital, Fudan University","Shanghai","Shanghai Municipality","200032","China","CN",{"type":47,"coordinates":48},"Point",[49,50],121.45806,31.22222,{"lat":50,"lon":49},[53],{"name":54,"role":35,"phone":55,"phoneExt":21,"email":56},"Mengjie Yang","+86 21 31587871","yang.mengjie@zs-hospital.sh.cn",{"type":58,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100556874","phase-2-cryoablation-combined-with-pd-1-antibody-and-bevacizumab-for-hepatocellular-carcinoma-100556874",false,"NCT06530784","Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma","Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma After Progression of PD-1\u002FL1 Antibody Treatment: a Pilot Clinical Study","Inclusion Criteria:\n\n1. Age between 18 and 80 years old, and expected survival is longer than 3 months\n2. Clinically or pathologically diagnosed as primary hepatocellular carcinoma\n3. Disease progression assessed according to mRECIST criteria after PD-1\u002FL1 antibody treatment\n4. Child-Pugh score of liver function A\u002FB (\\\u003C 7)\n5. At least one lesion is suitable for mRECIST assessment\n6. Strength score (ECOG): 0-1\n7. The patient and\u002For family members agree to join the clinical trial and sign the informed consent form\n\nExclusion Criteria:\n\n1. Patients whose tumor lesions are not suitable for ablation as assessed by the surgeon\n2. Tumor burden greater than ≥70%, or tumor is not suitable for mRECIST standard evaluation\n3. Patients with chronic viral hepatitis (hepatitis B, hepatitis C) have a viral load greater than 10\\^4 before receiving treatment or do not continue to take antiviral drugs regularly\n4. Pregnant patients\n5. Combined with other malignant tumors, or have a history of other malignant tumors within 3 years\n6. Active autoimmune disease, confirmed immunodeficiency, history of systemic steroid medication\n7. Severe renal dysfunction: creatinine (Cr) \\> 2 mg\u002FdL or creatinine clearance (CCr) \\\u003C30 mL\u002Fmin, severe heart, lung, brain and other important organ diseases\n8. History of gastrointestinal bleeding within 3 months\n9. Unable to cooperate with ablation surgery\n10. Severe gastroesophageal varices","ALL","18 Years","80 Years",{"count":70,"type":71},36,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1\u002FL1 antibody.",[77],"Carcinoma, Hepatocellular","NOT_YET_RECRUITING","2024-07-26",{"date":81,"type":82},"2024-07-31","ACTUAL",{"date":81,"type":71},{"date":85,"type":71},"2026-05-31",{"name":5,"class":6},1]